CLEC12A and leukemia: constructed a new CLL1 CAR using scFv from C57BL/6 mouse-derived CLL antibody, which has good anti-leukemia activity to U937 cell line and primary AML blasts in vitro and eliminated human AML in xenograft mouse models without targeting normal HSCs (140).